Drug
Imsidolimab
Imsidolimab: highest development phase Phase 3, developed by Vanda Pharmaceuticals. 4 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Vanda Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| 750 mg Imsidolimab NCT05352893 | Phase 3 | Generalized Pustular Psoriasis |
| Imsidolimab NCT03619902 | Phase 2 | Generalized Pustular Psoriasis |
| Imsidolimab NCT04856930 | Phase 2 | Hidradenitis Suppurativa |
| Imsidolimab NCT04697069 | Phase 2 | Acneiform Eruptions |
Latest
No recent events.
Follow Imsidolimab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.